|
|
Article: New River Pharmaceuticals Inc. Meets Enrollment in NRP104 Adult Phase III Study.
- Article from:
- PR Newswire
- Article date:
- September 12, 2006
CopyrightCOPYRIGHT 2006 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
RADFORD, Va., Sept. 12 /PRNewswire-FirstCall/ -- Presenting today at the Bear Stearns 19th Annual Healthcare Conference, New River Pharmaceuticals Inc. announced that the enrollment numbers have been met for the company's NRP104.303 study, which will examine the safety and efficacy of NRP104 as a treatment for attention-deficit/hyperactivity disorder (ADHD) in adult populations (ages 18-52). Randal Kirk, New River's Chairman and CEO, and Krish Krishnan, CFO and COO, stated that the company expects to complete the study in Q4 2006, to announce top-line data in from the study in Q1 2007, and to file a supplemental new drug application for the adult indication in Q2 2007.